Unveiling the Risks and Hope of Psychedelic Mushrooms for Mental Health

Interest in psychedelic-assisted therapy is growing among researchers, clinicians, and individuals seeking more effective mental health treatment options. Substances such as psilocybin—found in certain mushrooms—and LSD are currently being tested in clinical studies for conditions like depression, anxiety, addiction, and trauma.

Advocates believe this approach has the potential to revolutionize psychiatric care. However, scientists caution that the effects are not consistent for everyone. While some patients experience profound improvements, others may face emotional distress or even worsening symptoms.

A recent international study led by Charité–Universitätsmedizin Berlin examined what differentiates positive treatment outcomes from adverse ones. Published in Nature Mental Health, the research aimed to identify which patients are most likely to benefit from psychedelic therapy, assisting doctors in making safer, more informed decisions.

Psychedelic drugs influence perception, emotions, and consciousness. During sessions, patients might encounter vivid thoughts, emotional breakthroughs, intense memories, or altered perspectives about themselves and the world around them. These experiences are believed to temporarily enhance brain plasticity, helping individuals break free from harmful thought patterns linked to depression and other mental health issues.

Interest has surged because some patients with severe treatment-resistant depression have reported remarkable progress after only one or two guided sessions. Still, scientists recognize that these treatments can be emotionally intense and unpredictable.

The study highlighted two women with similar backgrounds: both suffered from long-standing, severe depression unresponsive to medications and therapy. One underwent a supervised psilocybin session, describing it as challenging yet deeply healing. Her emotional numbness lifted, and six weeks later, she showed no signs of depression on standard tests. The other woman experienced overwhelming emotions during her session, describing it as mental torture, and her depression persisted or worsened afterward.

This stark contrast led researchers to ask whether medical professionals can predict who will benefit from psychedelic therapy before treatment begins. To explore this, they surveyed 158 therapists worldwide, some practicing within authorized clinical trials, others working in unregulated underground settings. Data collected included patient personality traits, mental health history, therapy environments, support systems, preparation, supervision, and follow-up care.

Several patterns emerged: patients with stable lifestyles and strong social support systems were more likely to experience positive outcomes, possibly because emotional backing helps process difficult experiences during treatment. Personality traits also played a role, with better results seen in individuals who were emotionally open, curious about new experiences, and capable of accepting uncomfortable feelings instead of resisting them. Prior experience with meditation, controlled breathing, or other altered states of consciousness appeared beneficial, easing fear of unusual mental experiences during sessions. Conversely, ongoing substance use such as cocaine, amphetamines, alcohol, or cannabis correlated with less favorable results.

The study also warned that certain personality types might face higher risks. Patients displaying paranoid, schizoid, or schizotypal traits might experience increased confusion, fear, or emotional instability during altered states, highlighting the need for caution.

Findings underscore the complexity of psychedelic therapy, emphasizing that success depends not only on the drug but also on the environment, emotional readiness, therapist guidance, and post-treatment support. This holistic approach, often called “set and setting,” reflects how a patient’s mindset, expectations, surroundings, and therapist relationship can shape their experience.

Pre-treatment, it’s recommended that patients build trust with their therapists, openly discuss their goals, fears, and expectations. After sessions, ongoing follow-up helps patients process and integrate their experiences effectively.

The study also raised concerns about unregulated psychedelic treatments outside formal medical settings. While underground therapists sometimes report more optimistic results, experts stress that strict safety standards and scientific oversight are essential for patient safety.

Dr. Felix Betzler, who led the research, explained that while psychedelics have powerful potential, they also pose risks. He likened them to sharp tools that must be used with care and precision.

The researchers believe their findings are a step toward more personalized mental health care, where screening tools could identify patients most likely to benefit safely. Future efforts may include developing digital prediction methods based on data from therapists and patients.

Despite ongoing debate, the scientific community anticipates continued growth in psychedelic research. Nonetheless, a cautious approach remains vital, balancing hope with safety. While some individuals with severe mental illnesses may find life-changing relief through these therapies, careful patient selection, professional supervision, and comprehensive follow-up are key to ensuring safe and effective treatment.

If mental health matters to you, consider reviewing studies that identify core features of depression and explore how certain brain chemicals are linked to this condition. For more updates, check recent research on drugs impacting the brain and how new therapies compare to ketamine in treating severe depression.

This research was published in Nature Mental Health and conducted by Charité–Universitätsmedizin Berlin.